Publications & Articles

Pembrolizumab combined with low-dose cyclophosphamide and intra-tumoral injection of the toll-like receptor 4 agonist G100 in patients with advanced pretreated soft tissue sarcoma: results from the PEMBROSARC basket study
Journal of Hematology & Oncology, 2022, October 27

Mariella Spalato‑Ceruso, Fanny Bouteiller, Jean‑Philippe Guegan, Maud Toulmonde, Alban Bessede, Michèle Kind, Sophie Cousin, Xavier Buy, Jean Palussiere, François Le Loarer, Berengere Dadone‑Montaudie, Marina Pulido and Antoine Italiano

Annals of Oncology, 2022, July 15

F Peyraud, J-P Guegan, D Bodet, I Nafia, L Fontan, C Auzanneau, S Cousin, G Roubaud, M Cabart, F Chomy, F Le Loarer, N Chaput, F-X Danlos, D Planchard, C Even, M Khettab, L Tselikas, B Besse, F Barlesi, J-C Soria, A Marabelle, A Bessede, A Italiano

A novel gut-restricted small molecule TLR2 agonist enhances immune checkpoint inhibitor efficacy in a preclinical mouse fibrosarcoma tumor model
European journal of cancer, 2022, October 1
J. Simon, C.J. Oalmann, P. Stern, R.K. Senter, M. Chien, R. Graf, A. Bessede, A.S. Campbell

Mature tertiary lymphoid structure is a specific biomarker of cancer immunotherapy and does not predict outcome to chemotherapy in non-small cell lung cancer

In this collaborative work, researchers from Institut Bergonié, Institut Gustave Roussy, and Explicyte, demonstrated that presence of APAP in plasma from cancer patients before they undergo immunotherapy was independently associated with a worse clinical outcome.

Through this study, authors depicted the association between the enrichment of Tumor Associated Macrophages (TAMs) in the Tumor Micro Environment (TME) of Non-Small Cell Lung Cancer (NSCLC) and the resistance to immunotherapy, regardless of the programmed death ligand 1 status.